A Comparative Study of Vaginal Micronized Progesterone and Oral Dydrogesterone in Threatened Abortion
DOI:
https://doi.org/10.55489/ijmr.120420244Keywords:
Threatened abortion, progesterone, dydrogesterone, pregnancy outcomes, vaginal bleedingAbstract
Introduction: Threatened abortion, characterized by vaginal bleeding and abdominal pain in early pregnancy, requires effective management to improve pregnancy outcomes. Progestogens such as vaginal micronized progesterone and oral dydrogesterone are commonly used, yet limited comparative research exists to inform their optimal use. This study evaluates the efficacy and safety of these treatments in managing threatened abortion.
Methods: This prospective observational study, conducted at Saraswathi Institute of Medical Sciences, Hapur, U.P., included pregnant women with clinically and sonographically confirmed threatened abortion (≤24 weeks gestation). Participants were divided into two groups: one receiving 200 mg of vaginal micronized progesterone twice daily and the other 10 mg of oral dydrogesterone twice daily. Data collection included demographic details, bleeding episodes, and obstetric outcomes. Statistical analysis was performed, with significance set at p < 0.05.
Results: Baseline characteristics, including age and gestational parameters, were comparable between groups. Pregnancy continuation rates were 89.0% and 84.0% for oral dydrogesterone and vaginal progesterone, respectively (p = 0.30). Adverse effects were similar across groups, with no statistically significant differences.
Conclusion: Both oral dydrogesterone and vaginal progesterone demonstrated comparable efficacy and safety profiles in managing threatened abortion. The choice of treatment may depend on patient preferences and clinical circumstances.
References
1. Mouri MI, Hall H, Rupp TJ. Threatened Miscarriage. [Updated 2024 Feb 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430747/.
2. Chakravarty BN, Shirazee HH, Dam P, Goswami SK, Chatterjee R, Ghosh S. Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study. J Steroid Biochem Mol Biol 2005;97:416-20. DOI: https://doi.org/10.1016/j.jsbmb.2005.08.012 PMid:16213136
3. Arab H, Alharbi AJ, Oraif A, Sagr E, Al Madani H, Abduljabbar H, et al. The Role Of Progestogens In Threatened And Idiopathic Recurrent Miscarriage. Int J Womens Health 2019;11:589. DOI: https://doi.org/10.2147/IJWH.S224159 PMid:31807086 PMCid:PMC6848983
4. Sivasane DS, Daver RG. Study of pregnancy outcome of threatened abortion and its correlation with risk factors in a tertiary care hospital of Mumbai, India. Int J Reprod Contracept Obstet Gynecol 2018;7:4598. DOI: https://doi.org/10.18203/2320-1770.ijrcog20184514
5. Parveen R, Khakwani M, Tabassum S, Masood S. Oral versus Vaginal Micronized Progesterone for the Treatment of Threatened Miscarriage. Pak J Med Sci 2021;37:628. DOI: https://doi.org/10.12669/pjms.37.3.3700
6. Kale AR, Kale AA, Yelikar K. A Comparative, Randomized Control Trial in Patients of Per Vaginal Bleeding Comparing Efficacy of Oral Dydrogesterone Versus Vaginal Progesterone in Successful Pregnancy Outcome for Patients with Recurrent Pregnancy Loss. J Obstet Gynaecol India 2021;71:591. DOI: https://doi.org/10.1007/s13224-021-01473-2 PMid:34898896 PMCid:PMC8617090
7. Das R, Rout RR, Tiwari RVC, Tiwari HD, Ravuri P, Kommuri S, et al. Evaluation of per Vaginal Bleeding With Different Drugs in Successful Pregnancy in Patients With Recurrent Pregnancy Loss: An Original Research. J Pharm Bioallied Sci 2022;14:S193. DOI: https://doi.org/10.4103/jpbs.jpbs_90_22 PMid:36110650 PMCid:PMC9469287
8. Verma S, Yadav P. To Study the Comparison Between Oral Dydrogesterone and Micronized Progesterone in Threatened Miscarriage in Terms of Pain Lower Abdomen and Bleeding Per Vaginum. Ann. Int. Med. Den. Res. 2021; 7(1):OG11-OG15.
9. Sadaf, M. & Abbasi, N. Comparison of Efficacy of Oral Dydrogesterone VS Intramuscular Progesterone in terms of duration of cessation of vaginal bleeding in women with Threatened Abortion. Journal of Rawalpindi Medical College 2019;23(4): 194-198.
10. Qing G, Hong Y, Feng X, Wei R. Comparison of oral dydrogesterone and intramuscular progesterone in the treatment of threatened abortion 2015; 31(3):223-227
11. Wang X xue, Luo Q, Bai W pei. Efficacy of progesterone on threatened miscarriage: Difference in drug types. J Obstet Gynaecol Res 2019;45:794-802. DOI: https://doi.org/10.1111/jog.13909 PMid:30632226
12. Ikechebelu JI, Dim CC, Eleje GU, Joe-Ikechebelu N, Okpala BC, Okam PC. A randomised control trial on oral dydrogesterone versus micronized vaginal progesterone pessary for luteal phase support in in vitro fertilization cycles. J Med Life 2023;16:62. DOI: https://doi.org/10.25122/jml-2022-0131 PMid:36873122 PMCid:PMC9979184
13. Siew JYS, Allen JC, Hui CYY, Ku CW, Malhotra R, Østbye T, et al. The randomised controlled trial of micronised progesterone and dydrogesterone (TRoMaD) for threatened miscarriage. Eur J Obstet Gynecol Reprod Biol 2018;228:319-24. DOI: https://doi.org/10.1016/j.ejogrb.2018.07.028 PMid:30077119
Downloads
Published
How to Cite
Issue
Section
License
The authors retain the copyright of their article, with first publication rights granted to Medsci Publications.
